Scientific and Clinical Advisory Board
Chairman: Prof. Mark L. Tykocinski, M.D.,
Professor Tykocinski is the inventor of the DSP technology and a leader in the field of immune regulation. He is Provost of the Thomas Jefferson University in Philadelphia and Dean of the school of medicine. Before joining the Jefferson University, Prof. Tykocinski was Chair of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania for over a decade.
Dr. Nabil Hanna, Ph.D.
Dr. Hanna is the former Executive Vice President for Research at Biogen/Idec Inc. Dr. Hanna led the IDEC research team through the discovery and pre-clinical development of Rituximab and Zevalin, two drugs now approved for therapy of non-Hodgkin's lymphoma.
Dr. Barry Sherman, M.D.
Dr. Sherman was Senior Vice President and Chief Medical Officer at Genentech for over a decade. While at Genentech he led the clinical development of multiple blockbuster biological drugs.
Prof. Arnold Freedman, M.D.
Professor Freedman is a Professor of Medicine at Harvard Medical School and a leading expert on lymphoma drug clinical development. He is the Clinical Director of the Lymphoma Program at the Dana-Farber Cancer Institute's Department of Medical Oncology, and an attending physician at Brigham and Women's Hospital.